Table 1. Comparison of the characteristics and results of the COAPT and MITRA-FR trials.
| MITRA-FR | COAPT | |
|---|---|---|
| Total number of patients | 304 | 614 |
| Medical therapy | Adjusted in the trial | Optimized therapy |
| ≥ moderate to severe (3+) iMR | EROA > 20 mm2 and/or
RV > 30 mL |
EROA > 30 mm2 and/or RV > 45 mL |
| LVESD, mm (LV size) | Without limit | < 70 upon inclusion |
| NYHA class > II, % | 67.0 | 60.4 |
| Hospital in previous years, % | 100 | 57.1 |
| EROA, mm2 | 31 ± 10 | 41 ± 15 |
| Severe (EROA ≥ 40 mm2), % | 16 | 41 |
| iLVEDV, mL/m2 | 135 ± 35 | 101 ± 34 |
| 1-year mortality (IvsC), % | 24.2 ± 22.4 | 19.1 vs 23.2 (p < 0.001) |
| 1-year HF hospitalization (IvsC), % | 48.7 ± 47.4 | 35.8 vs 67.9 (p < 0.001) Primary objective |
| Annual mortality/ HF hospitalization (IvsC), % | 54.6 vs 51.3 (p = 0.53)
Primary objective |
33.9 vs 46.5 (p < 0.001) |
iMR: ischemic mitral regurgitation; EROA: effective regurgitant orifice area; RV: regurgitant volume; LVESD: left ventricular end-systolic diameter; NYHA: New York Heart Association; iLVEDV: indexed left ventricular end-diastolic volume; IvsC: Invasive vs Control; HF: heart failure.